Anticancer Therapy: Boosting the Bang of Bim

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2008 Oct 25

PMID 18949061

Citations 10

Authors

Andrea Wahner Hendrickson

Xue Wei Meng

Scott H Kaufmann

Affiliations

Soon will be listed here.

Abstract

Even though activating mutations of B-Raf, a kinase atop the MAPK signaling cascade, reportedly sensitize tumor cells to MEK inhibitors, Raf and MEK inhibitors have exhibited limited clinical activity. In this issue of the JCI, Cragg et al. report that MEK inhibition upregulates the proapoptotic Bcl-2 family member Bim but induces little regression of human melanoma xenografts in mice unless the Bcl-2 antagonist ABT-737 is added (see the related article beginning on page 3651). These findings illustrate the potential benefit of simultaneously inhibiting oncogenic kinases and inhibiting Bcl-2 action in solid tumors.

Citing Articles

The Vitamin D Receptor-BIM Axis Overcomes Cisplatin Resistance in Head and Neck Cancer.

Khamis A, Gul D, Wandrey M, Lu Q, Knauer S, Reinhardt C Cancers (Basel). 2022; 14(20).

PMID: 36291915 PMC: 9600548. DOI: 10.3390/cancers14205131.

Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach.

Lagana A, Beno I, Melnekoff D, Leshchenko V, Madduri D, Ramdas D JCO Precis Oncol. 2019; 2018.

PMID: 30706044 PMC: 6350920. DOI: 10.1200/PO.18.00019.

Overexpression of microRNA-1470 promotes proliferation and migration, and inhibits senescence of esophageal squamous carcinoma cells.

Mei L, Qiu Y, Wang W, Bai J, Shi Z Oncol Lett. 2018; 14(6):7753-7758.

PMID: 29344220 PMC: 5755030. DOI: 10.3892/ol.2017.7190.

Histone deacetylase inhibitors interrupt HSP90•RASGRP1 and HSP90•CRAF interactions to upregulate BIM and circumvent drug resistance in lymphoma cells.

Ding H, Peterson K, Correia C, Koh B, Schneider P, Nowakowski G Leukemia. 2016; 31(7):1593-1602.

PMID: 27890930 PMC: 5474223. DOI: 10.1038/leu.2016.357.

t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.

Christenson J, Denny E, Kane S Oncotarget. 2015; 6(32):33134-45.

PMID: 26430732 PMC: 4741754. DOI: 10.18632/oncotarget.5311.

References

Tuveson D, Weber B, Herlyn M . BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell. 2003; 4(2):95-8. DOI: 10.1016/s1535-6108(03)00189-2. View

Luciano F, Jacquel A, Colosetti P, Herrant M, Cagnol S, Pages G . Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene. 2003; 22(43):6785-93. DOI: 10.1038/sj.onc.1206792. View

Meng X, Chandra J, Loegering D, Van Becelaere K, Kottke T, Gore S . Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro. J Biol Chem. 2003; 278(47):47326-39. DOI: 10.1074/jbc.M304793200. View

Deng X, Gao F, Flagg T, May Jr W . Mono- and multisite phosphorylation enhances Bcl2's antiapoptotic function and inhibition of cell cycle entry functions. Proc Natl Acad Sci U S A. 2003; 101(1):153-8. PMC: 314154. DOI: 10.1073/pnas.2533920100. View

Ley R, Ewings K, Hadfield K, Howes E, Balmanno K, Cook S . Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem. 2003; 279(10):8837-47. DOI: 10.1074/jbc.M311578200. View

Dancey J . Predictive factors for epidermal growth factor receptor inhibitors--the bull's-eye hits the arrow. Cancer Cell. 2004; 5(5):411-5. DOI: 10.1016/s1535-6108(04)00122-9. View

Domina A, Vrana J, Gregory M, Hann S, Craig R . MCL1 is phosphorylated in the PEST region and stabilized upon ERK activation in viable cells, and at additional sites with cytotoxic okadaic acid or taxol. Oncogene. 2004; 23(31):5301-15. DOI: 10.1038/sj.onc.1207692. View

Walensky L, Kung A, Escher I, Malia T, Barbuto S, Wright R . Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science. 2004; 305(5689):1466-70. PMC: 1360987. DOI: 10.1126/science.1099191. View

Ito T, Deng X, Carr B, May W . Bcl-2 phosphorylation required for anti-apoptosis function. J Biol Chem. 1997; 272(18):11671-3. DOI: 10.1074/jbc.272.18.11671. View

10.

Rinehart J, Adjei A, LoRusso P, Waterhouse D, Hecht J, Natale R . Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 2004; 22(22):4456-62. DOI: 10.1200/JCO.2004.01.185. View

11.

Solit D, Garraway L, Pratilas C, Sawai A, Getz G, Basso A . BRAF mutation predicts sensitivity to MEK inhibition. Nature. 2005; 439(7074):358-62. PMC: 3306236. DOI: 10.1038/nature04304. View

12.

Eisen T, Ahmad T, Flaherty K, Gore M, Kaye S, Marais R . Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer. 2006; 95(5):581-6. PMC: 2360687. DOI: 10.1038/sj.bjc.6603291. View

13.

Kobayashi S, Lee S, Meng X, Mott J, Bronk S, Werneburg N . Serine 64 phosphorylation enhances the antiapoptotic function of Mcl-1. J Biol Chem. 2007; 282(25):18407-18417. DOI: 10.1074/jbc.M610010200. View

14.

Wang J, Wilcoxen K, Nomoto K, Wu S . Recent advances of MEK inhibitors and their clinical progress. Curr Top Med Chem. 2007; 7(14):1364-78. DOI: 10.2174/156802607781696837. View

15.

Adams J, Cory S . Bcl-2-regulated apoptosis: mechanism and therapeutic potential. Curr Opin Immunol. 2007; 19(5):488-96. PMC: 2754308. DOI: 10.1016/j.coi.2007.05.004. View

16.

Youle R, Strasser A . The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2007; 9(1):47-59. DOI: 10.1038/nrm2308. View

17.

Madhunapantula S, Robertson G . Is B-Raf a good therapeutic target for melanoma and other malignancies?. Cancer Res. 2008; 68(1):5-8. DOI: 10.1158/0008-5472.CAN-07-2038. View

18.

Chipuk J, Green D . How do BCL-2 proteins induce mitochondrial outer membrane permeabilization?. Trends Cell Biol. 2008; 18(4):157-64. PMC: 3242477. DOI: 10.1016/j.tcb.2008.01.007. View

19.

Weinstein I, Joe A . Oncogene addiction. Cancer Res. 2008; 68(9):3077-80. DOI: 10.1158/0008-5472.CAN-07-3293. View

20.

Cragg M, Jansen E, Cook M, Harris C, Strasser A, Scott C . Treatment of B-RAF mutant human tumor cells with a MEK inhibitor requires Bim and is enhanced by a BH3 mimetic. J Clin Invest. 2008; 118(11):3651-9. PMC: 2571034. DOI: 10.1172/JCI35437. View